Filed pursuant to Rule 424(b)(3)
Registration No. 333-187466
PROSPECTUS SUPPLEMENT NO. 9
(to Prospectus dated July 21, 2013)
5,369 Shares of Series C 8% Convertible Preferred Stock
(and 2,753,348 Shares of Common Stock Underlying the Series C 8% Convertible Preferred Stock)
Warrants to Purchase up to 2,753,348 Shares of Common Stock
(and 2,753,348 Shares of Common Stock Issuable From Time to Time Upon Exercise of Warrants)
This prospectus supplement modifies and supplements the prospectus of Oxygen Biotherapeutics, Inc. (the “Company”) dated July 21, 2013 (as supplemented on July 25, 2013, July 31, 2013, August 13, 2013, August 23, 2013, August 26, 2013, September 17, 2013 and October 25, 2013) relating to 5,369 shares of Series C 8% Convertible Preferred Stock (and 2,753,348 shares of common stock issuable upon conversion of the Series C 8% Convertible Preferred Stock) and warrants exercisable for 2,753,348 shares of common stock at an exercise price of $2.60 per share (and 2,753,348 shares of common stock issuable upon exercise of the warrants).
This prospectus supplement should be read in conjunction with, and may not be delivered or utilized without, the prospectus. This prospectus supplement is qualified in its entirety by reference to the prospectus, except to the extent that the information in this prospectus supplement supersedes the information contained in the prospectus.
This prospectus supplement includes the attached Current Report on Form 8-K, as filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2013.
NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this prospectus supplement is November 8, 2013.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2013
Oxygen Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-34600 | 26-2593535 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address of principal executive offices) (Zip Code)
919-855-2100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
From November 4, 2013 through November 6, 2013, outstanding warrants to purchase an aggregate of 2,294,874 shares of common stock of Oxygen Biotherapeutics, Inc. (the “Company”) were exercised for net proceeds to the Company of approximately $6.0 million. These warrants were issued by the Company in connection with its July 2013 financing. Following these warrant exercises, 9,112,307 shares of the Company’s common stock were issued and outstanding as of November 7, 2013.
On November 8, 2013, the Company issued a press release (the “Press Release”) regarding the exercise of the warrants described above.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description |
Exhibit 99.1 | Press Release dated November 8, 2013. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Oxygen Biotherapeutics, Inc. | |||
Date: November 8, 2013 | By: | /s/ Michael B. Jebsen | |
Michael B. Jebsen | |||
Chief Financial Officer and Interim Chief Executive Officer | |||
3
Exhibit Index
Exhibit No. | Description |
Press Release dated November 8, 2013. |
4